Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
PharmacologySpecial Sessions

SOLACI-CACI 2021 | DAPT Session

solaci
solaci
606
0

✔️ Watch again the DAPT Session in the SOLACI-CACI 2021 Congress.

👨‍🏫 Program:

  • 02:58 – Short versus long-term DAPT Therapy in High Risk Bleeding. Rationality and Preliminary Results of Master DAPT trial – Peter Smits.
  • 31:20 – Rationality of long-term DAPT in Chronic Stable Angina – Ernesto Duronto.
  • 48:14 – Selection of the best P2Y12 in Patients with ACS and STEMI: Evidence from Registries – Alfredo E. Rodríguez. 58:55 – Current Indication of Ticagrelor – Roxana Merhan.
  • 01:07:25 – Prasugrel or Ticagrelor in Acute Coronary Syndromes: the ISAR-REACT Trial – Adnan Kastrati.

👉🏻 Panelists: Curotto, Valeria – Iglesias, Ricardo – Piraino, Rubén – Pocoví , Antonio – Salvatori, Carolina – Santaera, Omar – Sztutzbach, Pablo G.
👉🏻 Chairpersons: José Mangione & Fausto Feres

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
Asymptomatic Carotid Lesions and Cognitive Impairment: Does Intervention Play a Role?
Next article
SOLACI-CACI 2021 | Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic
solaci
solaci

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Dr. Omar Tupayachi - 0
Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

Dr. Omar Tupayachi - 0
The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

Dr. Omar Tupayachi - 0
The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 0
Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Acute coronary syndromes

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset...
Dr. Omar Tupayachi -
SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Dr. Omar Tupayachi - 0
Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Dr. Omar Tupayachi - 0
Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Dr. Omar Tupayachi - 0
Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...